Fig. 1From: Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemiaAdmission electrocardiogram demonstrating sinus tachycardia (left upper) with negative T waves in leads V1-V3 and admission chest radiograph showing no acute cardiopulmonary disease (left lower). After four doses of gilteritinib and five days after admission, a repeat electrocardiogram is unremarkable (upper right). A repeat chest radiograph demonstrates interval cardiomegaly and diffuse pulmonary interstitial edema (lower right)Back to article page